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In this data article, the potential role of p53 tumor suppressor gene
(p53) on the attachment ability of MCF-7 breast cancer cells was
investigated. In our main article, “IGF-I/ EGF and E2 signaling
crosstalk through IGF-IR conduit point affect breast cancer cell
adhesion” (K. Voudouri, D. Nikitovic, A. Berdiaki, D. Kletsas, N.K.
Karamanos, G.N. Tzanakakis, 2016) [1], we describe the key role of
IGF-IR in breast cancer cell adhesion onto ﬁbronectin (FN). p53
tumor suppressor gene is a principal regulator of cancer cell pro-
liferation. Various data have demonstrated an association between
p53 and IGF-IR actions on cell growth through its’ putative reg-
ulation of IGF-IR expression. According to our performed experi-
ments, p53 does not modify IGF-IR expression and does not affect
basal MCF-7 cells adhesion onto FN. Moreover, technical details
about the performance of adhesion assay onto the FN substrate
were provided.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.matbio.2016.06.005
kis).
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factorsFibronectin as a substrate for the adhesion assay, transfection with siRNA spe-
ciﬁc for p53xperimental
featuresVarious numbers of cells were plated onto FN to optimize cell number and
adhesion time in order to design a tailor-made adhesion assay for MCF-7 cells.
The attachment ability of cells and the expression of IGF-IR were assessed after
transfection of cells with siRNA speciﬁc for p53 gene.ata source
locationDepartment of Anatomy- Histology- Embryology, School of Medicine, University
of Creteata accessibility Data are provided with this articleD
Value of the data
 There is an established connection between p53 and IGF-IR activities in cancer; speciﬁcally p53
mutant forms are known to enhance IGF-IR gene expression (2–5). The assessment of p53/IGF-IR
interactions in breast cancer cell adhesion can be of value for research groups from related ﬁelds.
 These data can be compared to other scientiﬁc data addressing the connection between various
tumor suppressor genes and IGF-IR expression and/or to data of this interaction in other cell lines
and functions.
 These data facilitates other researchers to execute the optimum adhesion assay for the evaluation
of MCF-7 cell adhesion onto FN.1. Data
This article contains graphs presenting data on the role of p53 tumor-suppressor gene[2-5] in IGF-
IR expression and breast cancer cell adhesion (Fig. 1). Furthermore, technical details for the perfor-
mance of the MCF-7 cells’ adhesion assay including number of plated cells and the adherence time for
the MCF-7 cell adhesion protocol, are included (Fig. 2). Utilized reagents are presented in Table 1.2. Experimental design, materials and methods
In order to optimize the adhesion assay protocol we utilized various cell seeding numbers and
adhesion times. Cell lines and cell culture conditions are presented in [1]. In this article additional
technical features of cell adhesion assay are provided.
2.1. Real time PCR, Western blot, adhesion assay
Adhesion assay, siRNA transfection with siRNA speciﬁc for p53, real time PCR and western blot
experiments were designed to examine the role of p53 in MCF-7 FN-dependent adhesion. RNA
interference, Western Blot, Real time PCR and adhesion assay protocols were described in [1]. Here,
we provide extra information describing the characteristics of utilized siRNA speciﬁc for p53, p53
antibody and p53 primer (Table 1).
Fig. 1. The role of p53 in breast cancer cell adhesion and IGF-IR expression. MCF-7 cells were transfected with p53 short
interfering RNA (sip53), where scramble RNA (siScr) was used as a negative control. The cells were cultured for 48 h before
harvesting. (A), Representative blot of p53 protein (53kDa) band is presented; (B) p53 protein bands were densitometrically
analyzed and adjusted against actin. (C), p53 mRNA levels expression was veriﬁed by real time PCR; (D), MCF-7 cells were
transfected with p53 short interfering RNA (si53) with the use of scramble RNA (siScr) as a negative control. The cells were
cultured for 48 h before harvest and IGF-IR protein levels were veriﬁed with Western blotting; (E), p53 protein bands (p53kDa)
were densitometrically analyzed and adjusted against actin. The results represent the average of three separate experiments in
triplicates. Mean7SEM plotted; (F), MCF-7 cells were transfected with p53 short interfering RNA (sip53) with the use of
scramble RNA (siscr) as a negative control. The cells were cultured for 48 h before harvesting and reseeding for 1 h on 96 well-
plates coated with FN. The number of attached cells was determined using ﬂuometric CyQUANT Assay Kit (Molecular Probes).
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The 96-well plates were coated with FN (Milipore) (5 μg/ml) as described in (1). MCF-7 cells were
detached with 5 mM PBSEDTA. Cells at 3000, 6000 and 9000 cell/well were seeded onto FN coated
96-well plate. In this experiment, the cells were allowed to adhere or 30 min. The 6000 cells/well
Table 1
Biochemical reagents utilized for the p53 experiment.
p53 antibody (Santa Cruz
Biotechnology)
Sc-126
p53 primer (VBC- Biotech) F 50- CGT CTG GGC TTC TTG CAT TC-30
R 50- AAG ACC TGC CCT GTG CAG C-30
p53 siRNA 50-CAGTCTACCTCCCGCCATA-30
50-GAAGAAACCACTGGATGGA-30
Fig. 2. Adhesion assay optimization. MCF-7 cells were cultured for 48 h in serum- free conditions, before harvesting and
reseeding on 96-well plates coated with FN for 30 min at three different concentrations (3.000, 6.000 and 9.000 cells/well) (A).
6000 cells/well seeded for 30 min, 1 h, 1,5 h, 2 h, 3 h on 96-well plates coated with FN for 1 h (B). The number of attached cells
was determined by ﬂuometric CyQUANT Assay Kit (Molecular Probes). The results represent the average of three separate
experiments in triplicates. Mean7SEM plotted.
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determine the optimum adhesion time the 6000 cells/well were allowed to adhere during 30 min,
1 h, 1,5 h, 2 h and 3 h, respectively. The number of adherent cells was determined as described in (1)Acknowledgements
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